

Original Article

Discovery of novel PTP1B inhibitors with antihyperglycemic activity

Zhang LIU^{1, #}, Qian CHAI^{1, #}, Yuan-yuan LI^{2, #}, Qiang SHEN², Lan-ping MA^{1, *}, Li-na ZHANG², Xin WANG¹, Li SHENG², Jing-ya LI², Jia LI^{2, *}, Jing-kang SHEN¹

¹The State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; ²The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

Aim: To discover and optimize a series of novel PTP1B inhibitors containing a thiazolidinone-substituted biphenyl scaffold and to further evaluate the inhibitory effects of these compounds *in vitro* and *in vivo*.

Methods: A total of 36 thiazolidinone substituted biphenyl scaffold derivatives were prepared. An *in vitro* biological evaluation was done by Enzyme-based assay. The *in vivo* efficacy of **7Fb** as an antihyperglycemic agent was evaluated in a BKS db/db diabetic mouse model with a dose of 50 mg·kg⁻¹·d⁻¹ for 4 weeks.

Results: The *in vitro* biological evaluation showed that compounds **7Fb** and **7Fc** could increase the insulin-induced tyrosine phosphorylation of IRβ in CHO/hIR cells. In *in vivo* experiments, compound **7Fb** significantly lowered the postprandial blood glucose, from 29.4±1.2 mmol/L with the vehicle to 24.7±0.6 mmol/L (*P*<0.01), and the fasting blood glucose from 27.3±1.5 mmol/L with the vehicle to 23.6±1.2 mmol/L (*P*<0.05).

Conclusion: A novel series of compounds were discovered to be PTP1B inhibitors. Among them, compound **7Fb** significantly lowered the postprandial and fasting glucose levels, and the blood glucose level declined more rapidly than in metformin-treated mice. Thus, **7Fb** may be a potential lead compound for developing new agents for the treatment of type II diabetes.

Keywords: protein tyrosine phosphatases (PTPs); diabetes; antihyperglycemic activity; drug screening

Acta Pharmacologica Sinica (2010) 31: 1005–1012; doi: 10.1038/aps.2010.81

Introduction

The protein tyrosine phosphatases (PTPs) constitute a family of closely related key regulatory enzymes that dephosphorylate phosphotyrosine residues in their protein substrates. They provide a necessary biological counterpart to protein kinases in signal transduction pathways and play an important role in the regulation of many cellular processes, including cell growth and differentiation, metabolism, cell migration, the immune response, cell apoptosis and bone development^[1–6]. Malfunctions in PTP activity lead to aberrant tyrosine phosphorylation and are linked to various diseases, such as diabetes, obesity, cancer, inflammation and neurodegenerative diseases^[7–10]. Therefore, the development of therapeutically promising potent PTP inhibitors is of great importance.

Protein tyrosine phosphatase-1B (PTP1B) is an intracellular

PTP that is implicated as a key negative regulator of the insulin and leptin signaling pathways^[11–13]. It acts by dephosphorylating specific phosphotyrosine (pTyr) residues on the insulin receptor and on insulin receptor substrate proteins^[7, 11, 14–16]. Two landmark papers reported that PTP1B deficient mice are more sensitive to insulin, have improved glycemic control, and are resistant to diet induced obesity^[17, 18]. Furthermore, treatment of diabetic mice with PTP1B antisense oligonucleotides reduced the expression level of this enzyme and subsequently normalized blood glucose levels and improved insulin sensitivity^[19, 20]. A PTP1B inhibitor may provide a novel strategy for the treatment of type II diabetes and obesity. Recent studies have shown that PTP1B also plays a role in tumorigenesis^[10, 21]. As a result, PTP1B inhibitors represent attractive pharmaceutical agents for treating type II diabetes, obesity, and cancer. Thus, over the past decade, numerous PTP1B inhibitors have been developed to be used as drug candidates^[22–25]. Most of the reported compounds have exhibited excellent potency (at nanomolar concentrations) in *in vitro* studies, but the low cell permeability and poor bioavailability of these compounds


These authors contributed equally to this work.

* To whom correspondence should be addressed.

E-mail lpma@mail.shcnc.ac.cn (Lan-ping MA);

jli@mail.shcnc.ac.cn (Jia LI)

Received 2010-04-29 Accepted 2010-05-27



Scheme 1. Reagents and conditions: a) 4-Bromo benzaldehyde, MeOH, 50 °C, 6 h; b) Ar-B(OH)₂ (4A-4D), 1 mol% Pd(OAc)₂, K₂CO₃, MeOH, 80 °C, 8 h; c) Cleavage reagents, AcOH, NaOAc, 120 °C, 12 h; d) Rb-Br (6A-6I), K₂CO₃, CH₃CN, 80 °C, 12 h.

have limited their application for the development of effective drugs^[26-28]. Therefore, PTP1B inhibitors still represent a challenge for medicinal chemists.

Compounds of the thiazolidinedione (TZD) class have aroused considerable interest as antihyperglycemic compounds and aldose reductase inhibitors^[29-31]. Some of these compounds (such as pioglitazone and rosiglitazone) are insulin-sensitizing agents acting as peroxisome proliferator-activated receptor γ (PPAR γ) agonists^[30], and they have been shown to be effective in treating type II diabetes in clinical situation. In addition, some 2,4-TZDs have proved to be PTP1B inhibitors^[32].

In our previous work, we have reported the discovery of PTP1B inhibitors from our combinatorial library, in which the thiazolidinedione moiety and substituted biphenyl scaffold were found to be effective^[33]. Here we describe our efforts to extend the SAR studies leading to more potent PTP1B inhibitors with antihyperglycemic activity *in vivo*.

Materials and methods

Chemistry

The general method of synthesis for the compounds is depicted in Scheme 1. 4-Bromo benzaldehyde was attached to the amino functionalized PEG support via an imine linkage, and Suzuki coupling was subsequently performed to give polymer **4**. Products **5Aa-5Cc** were obtained from the cleavage reaction of polymer **4** with different cleavage agents (Scheme 1)^[33]. Since 4'-substituted compounds were identified as more potent PTP1B inhibitors, additional diversity was introduced at the 4'-position of the biphenyl scaffold. Polymer **3** was reacted with halides **6A-6I** and then released from the PEG support using the same cleavage strategy to afford products **7Aa-7Ic**. This process generally provided the final products in >75 % yield with >85 % purity.

In vitro enzyme assays

Enzyme-based assay of PTP1B

A colorimetric high throughput assay to measure inhibition against PTP1B was performed in 96-well plates. Briefly, the


tested compounds were solubilized in DMSO and serially diluted into concentrations for the inhibitory test. The assays were carried out in a final volume of 100 μ L containing 50 mmol/L MOPS, pH 6.5, 2 mmol/L pNPP, 30 nmol/L GST-PTP1B, and 2% DMSO, and the catalysis of pNPP was continuously monitored on a SpectraMax 340 microplate reader at 405 nm for 2 min at 30 °C. The IC₅₀ value was calculated from the nonlinear curve fitting of the percent inhibition [inhibition (%)] vs the inhibitor concentration [I] using the following equation: %inhibition=100/{1+(IC₅₀/[I])^k}, where *k* is the Hill coefficient.

Enzyme-based assay of PTP1s

PTPase family members, such as Src homology domain 2 (SH2)-containing tyrosine phosphatase-1 (SHP1), Src homology domain 2 (SH2)-containing tyrosine phosphatase-2 (SHP2), leukocyte antigen-related phosphatase (LAR), CDC25B and PRL-3, were prepared for the selectivity assay of compounds as previously mentioned^[34]. Assays for these PTPases were performed at the optimal pH for each individual enzyme activity. These enzymes and inhibitors were preincubated for 3 min at 4 °C, and the assays were initiated by adding substrates. Assays performed for CDC25B, SHP1 and SHP2, LAR and PRL-3 were done using OMFP as a substrate.

In vivo efficacy study on diabetic BKS db/db mouse

C57BLKS/J-db/db mice were introduced from Jackson Laboratories. At the age of 8 weeks, db/db mice were randomized into the various treatment groups by body weight and random-fed glucose levels. Mice were orally administered once daily with 50 mg/kg per day **7Fb** and 150 mg/kg per day metformin. The diabetic and wildtype mice were gavaged with 5% methycellulose (MC) as control group for 4 weeks. The random-fed and fasting blood glucose were tested after 4 weeks treatment. The glucose tolerance test was performed after 6 h fasting and blood glucose were recorded in 0-120 min after 2 g/kg glucose ip injection. Difference between groups was analyzed by Student's *t*-test. All animal experiments were approved by the Animal Ethics Committee of the Shanghai Institute of Materia Medica.

Table 1. *In vitro* activity against PTP1B.

Compd	Z	X	Y	IC ₅₀ ^a (μmol/L)
5Aa		O	H	1.48±0.06
5Ab		S	H	1.69±0.24
5Ac		S	-CH ₂ COOH	0.53±0.10
5Ba		O	H	4.61±0.40
5Bb		S	H	2.40±0.15
5Bc		S	-CH ₂ COOH	1.43±0.18
5Ca		O	H	4.18±0.10
5Cb		S	H	0.82±0.03
5Cc		S	-CH ₂ COOH	2.04±0.20
7Aa		O	H	7.79±0.44
7Ab		S	H	4.28±1.04
7Ac		S	-CH ₂ COOH	3.87±0.10
7Ba		O	H	2.28±0.18
7Bb		S	H	1.42±0.20
7Bc		S	-CH ₂ COOH	2.24±0.32
7Ca		O	H	7.46±0.17
7Cb		S	H	1.91±0.00
7Cc		S	-CH ₂ COOH	3.34±0.19
7Da		O	H	12.78±0.48
7Db		S	H	2.11±0.19
7Dc		S	-CH ₂ COOH	2.60±0.56
7Ea		O	H	4.16±0.28
7Eb		S	H	1.71±0.14
7Ec		S	-CH ₂ COOH	2.39±0.02
7Fa		O	H	1.34±0.13
7Fb		S	H	0.69±0.07
7Fc		S	-CH ₂ COOH	0.48±0.07
7Ga		O	H	3.66±0.18
7Gb		S	H	1.26±0.10
7Gc		S	-CH ₂ COOH	1.10±0.17
7Ha		O	H	2.59±0.17
7Hb		S	H	1.24±0.14
7Hc		S	-CH ₂ COOH	2.55±0.53
7Ia		O	H	2.53±0.27
7Ib		S	H	1.20±0.12
7Ic		S	-CH ₂ COOH	1.86±0.22

Results and discussion

Inhibitory activities toward PTP1B

Compounds **5Aa–5Cc** and **7Aa–7Ic** were evaluated *in vitro* for their inhibitory activity against PTP1B (Table 1). As illustrated in Table 1, most of these compounds exhibited moderate inhibitory activity, with IC₅₀ values around 10⁻⁶ mol/L. When comparing **5(A–C)a** and **7(A–I)a** to **5(A–C)(b, c)** and **7(A–I)(b, c)**, we found that compounds containing a 4-oxothiazolidine-2-thione moiety showed better inhibitory activity against PTP1B. Introduction of an acetic group in the N position of the 4-oxothiazolidine-2-thione moiety made little impact on its activity. Bulky substituents at the 4'-position of the biphenyl scaffold led to favorable bioactivity. Generally, the aryl substituents at the 4'-position provided better inhibition of PTP1B than the alkyl substituent. The length of the linker between the biphenyl scaffold and the aryl group also influenced the inhibitory activity. Benzyl substituents gave the best results in **7Fc** and **7Fb**, with IC₅₀ values of 0.48±0.07 μmol/L and 0.69±0.07 μmol/L, respectively.

Furthermore, **7Fb** and **7Fc** were screened against a panel of six members of the PTPase family (Table 2). In contrast to the poor selectivity of **7Fc**, compound **7Fb** exhibited high selectivity against several other therapeutically useful phosphatases (*ie*, SHP1, SHP2, LAR, *etc*).

Cellular and *in vivo* activity of selected compounds



In the next step, we evaluated the two potent inhibitors of PTP1B, **7Fb** and **7Fc**, in CHO/hIR cells according to our previous method^[35]. CHO/hIR cells were incubated with several concentrations of compounds **7Fb** and **7Fc** (1.1 μmol/L, 3.3 μmol/L and 10 μmol/L) for 2 h. This was followed by treatment with 10 nmol/L insulin for 10 min (Figure 1). DMSO (0.2%) and orthovanadate (1 mmol/L) were used as negative and positive controls, respectively. The cell lysates were subjected to SDS-PAGE, transferred to a nitrocellulose membrane, and probed with specific anti-pTyr^{1162/1163} IR antibodies. As shown in Figure 1, both compounds increased the insulin-induced tyrosine phosphorylation of IRβ and compound **7Fb** (1.1 μmol/L) boosted IR phosphorylation more potently.

Based on the selective inhibition of PTP1B by **7Fb** and its cellular activity of increasing IR phosphorylation, the efficacy study was further investigated in a diabetic mouse model. *In vivo* efficacy of **7Fb** as an antihyperglycemic agent was evaluated in a BKS db/db diabetic mouse model at a dose of 50 mg/kg per day for 4 weeks. Compound **7Fb** significantly lowered the postprandial blood glucose from 29.4±1.2 mmol/L with the vehicle to 24.7±0.6 mmol/L (*P*<0.01) and the fasting blood glucose from 27.3±1.5 mmol/L with the vehicle to 23.6±1.2 mmol/L (*P*<0.05). The impaired glucose tolerance capacity of the diabetic mice was also significantly improved after prolonged **7Fb** treatment, and the area under the curve (AUC) was decreased to 3829.5±208.5 mmol/L·min from 4404.4±100.1 mmol/L·min. The blood glucose level declined more rapidly than in metformin treated mice (150 mg/kg) (Figure 2).

Taken together, the cellular effect of PTP1B inhibition on the

Table 2. Selectivity of **7Fb** and **7Fc** for a panel of protein phosphatases.


Compd	IC ₅₀ (μmol/L)					
	PTP1B	LAR	Cdc25B	SHP1	SHP2	PRL3
7Fb	0.69±0.07	>50	2.22±0.14	>50	>50	5.34±1.42
7Fc	0.48±0.07	>50	0.89±0.03	1.90±0.17	1.61±0.13	2.07±0.50

**Figure 1.** Effects of **7Fb** and **7Fc** on tyrosine phosphorylation of IRβ in CHO/hIR cells. The tyrosine phosphorylation level were determined by specific antibody of phosphorylated IR-Tyr^{1162/1163} with or without treatment, the β-actin represents the sample amount loaded. BL1 and BL2, 0.2% DMSO; PC, 1 mmol/L orthovanadate; and the compound concentration unit is μmol/L.

insulin receptor critical tyrosine phosphorylation and the *in vivo* efficacy of **7Fb** in improving the glucose tolerance capacity and blood glucose suggested that PTP1B inhibition was greatly involved in compound **7Fb**'s bioactivity, but an alternative mode of PPAR activation was not excluded.

Conclusion

In summary, with the methods developed for the synthesis of a biphenyl thiazolidinone library, we have found a series of

**Figure 2.** Glucose tolerance capacity improved by **7Fb**. Diabetic BKS db/db mice were treated orally with **7Fb** or metformin, the diabetic and wild-type mice were gavaged with 5% methylcellulose (MC) as control group for 4 weeks. The glucose tolerance test (2 g/kg glucose ip) was performed after 6 h fasting and blood glucose level at the above time-points were recorded. Differences between groups were analyzed by Student's *t*-test. ^b*P*<0.05, ^c*P*<0.01 vs BKS-Veh.

novel PTP1B inhibitors that exhibited submicromolar potency. Among the compounds, **7Fb** was tested in an animal model for its efficacy as an anti-diabetic agent. Compound **7Fb** significantly lowered the postprandial and fasting glucose levels and improved the glucose tolerance in the db/db diabetic mice; thus, it may be a potential lead compound for the generation of a therapy for type II diabetes.

Appendix

The reagents (chemicals) were purchased from Lancaster (Morecambe, England), Acros (Geel, Belgium) and Shanghai Chemical Reagent Company (Shanghai, China) and used without further purification. The analytical thin-layer chromatography was done using HSGF 254 (150–200 μm thickness; Yantai Huiyou Company, Yantai, Shandong, China). The ¹H NMR (300 MHz or 400 MHz) spectra were recorded on a Varian Mercury-300 or 400 High Performance Digital FT-NMR with TMS as an internal standard, and the ¹³C NMR (100 MHz) spectra were determined using a Varian Mercury-400 High Performance Digital FT-NMR. Chemical shifts were reported in parts per million (ppm, δ) downfield from tetramethylsilane. Proton coupling patterns were described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), and broad (br). EI-MS and HRMS were performed with a Finnigan MAT 95, EI: 70 eV, R: 10 000. Purity was recorded on a Gilson high-performance liquid chromatography (HPLC) system (306

pump, UV/vis-156 Detector, 215 liquid handle).

General procedures for the preparation of compounds 5Aa–5Cc and 7Aa–71c

Compounds **5Aa–5Cc** and **7Aa–71c** were prepared as previously mentioned^[27].

(Z)-5-((4'-phenylbiphenyl-4-yl)methylene)thiazolidine-2,4-dione (5Aa)

¹H NMR (300 MHz, d₆-DMSO): δ 7.92 (d, J=8.5 Hz, 2H), 7.87 (d, J=8.5 Hz, 2H), 7.81(m, 3H), 7.73 (m, 4H), 7.49 (m, 2H), 7.38 (m, 1H); ¹³C NMR (100 MHz, d₆-DMSO): 167.845, 167.362, 141.204, 139.933, 139.423, 137.765, 132.181, 131.370, 130.824(×2), 129.079(×2), 127.772, 127.371(×4), 127.312(×2), 126.661(×2), 123.367; EI-MS: *m/z* 357 (M), 286; HRMS: calculated for C₂₂H₁₅NO₂S, 357.0823, found 357.0832; HPLC Purity (retention time): 100% (4.54 min)

(Z)-5-((4'-phenylbiphenyl-4-yl)methylene)-2-thioxothiazolidin-4-one (5Ab)

¹H NMR (300 MHz, d₆-DMSO): δ 7.93 (d, J=8.4 Hz, 2H), 7.87 (d, J=8.4 Hz, 2H), 7.80 (d, J=8.5 Hz, 2H), 7.73 (m, 5H), 7.49 (m, 2H), 7.39 (m, 1H); EI-MS: *m/z* 373 (M), 286; HPLC Purity (retention time): 98% (4.92 min)

(Z)-2-[4-oxo-5-[(4'-phenylbiphenyl-4-yl)methylene]-2-thioxothiazolidin-3-yl]acetic acid (5Ac)

¹H NMR (300 MHz, d₆-DMSO): δ 7.92 (m, 3H), 7.89 (d, J=8.5 Hz, 2H), 7.85 (d, J=8.5 Hz, 2H), 7.79 (m, 4H), 7.51 (m, 2H), 7.40 (m, 1H), 4.73 (s, 2H); EI-MS: *m/z* 431 (M), 306, 286; HPLC Purity (retention time): 96% (3.94 min)

(Z)-5-((4'-2-fluorophenylbiphenyl-4-yl)methylene)thiazolidine-2,4-dione (5Ba)

¹H NMR (300 MHz, d₆-DMSO): δ 7.96 (d, J=8.5 Hz, 2H), 7.80 (m, 2H), 7.65–7.74 (m, 4H), 7.61 (d, J=8.4 Hz, 2H), 7.50 (m, 2H), 7.43 (m, 1H); ¹³C NMR (100 MHz, d₆-DMSO): 167.722, 167.235, 159.544 (d, J_{C-F}=244.6 Hz), 140.179, 139.806, 134.631, 132.741, 131.338, 131.234, 130.773(×2), 128.742(×3), 128.095, 127.909, 127.476(×2), 123.686, 123.172, 114.431, 114.185; EI-MS: *m/z* 375 (M), 304; HRMS: calculated for C₂₂H₁₄NO₂FS, 375.0729, found 375.0730; HPLC Purity (retention time): 98% (4.37 min)

(Z)-5-((4'-2-fluorophenylbiphenyl-4-yl)methylene)-2-thioxothiazolidin-4-one (5Bb)

¹H NMR (300 MHz, d₆-DMSO): δ 7.97 (d, J=8.5 Hz, 2H), 7.79 (m, 1H), 7.65–7.74 (m, 5H), 7.61 (d, J=8.3 Hz, 2H), 7.51 (m, 2H), 7.43 (m, 1H); EI-MS: *m/z* 391 (M), 304; HPLC Purity (retention time): 97% (4.76 min)

(Z)-2-(4-oxo-5-((4'-2-fluorophenylbiphenyl-4-yl)methylene)-2-thioxothiazolidin-3-yl)acetic acid (5Bc)

¹H NMR (300 MHz, d₆-DMSO): δ 7.98 (d, J=8.4 Hz, 2H), 7.92 (s, 1H), 7.79 (m, 1H), 7.68–7.76 (m, 4H), 7.66 (d, J=8.3 Hz, 2H), 7.54 (m, 2H), 7.43 (m, 1H), 4.75 (s, 2H); EI-MS: *m/z* 449 (M), 304, 226; HPLC Purity (retention time): 98% (3.81 min)

(Z)-5-((4'-phenoxybiphenyl-4-yl)methylene)thiazolidine-2,4-dione (5Ca)

¹H NMR (300 MHz, d₆-DMSO): δ 7.82 (m, 3H), 7.77 (d, J=8.3 Hz, 2H), 7.67 (d, J=8.3 Hz, 2H), 7.42 (m, 2H), 7.18 (t, J=7.2 Hz, 1H), 7.09 (m, 4H); ¹³C NMR (100 MHz, d₆-DMSO): 167.813, 167.326, 157.205, 156.198, 141.095, 133.802, 131.780, 130.787(×2), 130.209(×2), 128.542(×2), 127.544, 127.116(×2), 123.941, 123.144, 119.150(×2), 118.799(×2); EI-MS: *m/z* 373 (M), 302, 225; HRMS: calculated for C₂₂H₁₅NO₃S, 373.0773, found 373.0771; HPLC Purity (retention time): 100% (4.52 min)

(Z)-5-((4'-phenoxybiphenyl-4-yl)methylene)-2-thioxothiazolidin-4-one (5Cb)

¹H NMR (300 MHz, d₆-DMSO): δ 7.85 (d, J=8.5 Hz, 2H), 7.78 (d, J=8.5 Hz, 2H), 7.69 (m, 3H), 7.43 (m, 2H), 7.19 (t, J=7.5 Hz, 1H), 7.09 (m, 4H); ¹³C NMR (100 MHz, d₆-DMSO): 195.315, 169.257, 157.264, 156.139, 141.350, 133.643, 131.639, 131.247(×2), 130.181(×2), 128.528(×2), 127.581, 127.162(×2), 124.966, 123.937, 119.154(×2), 118.744(×2); EI-MS: *m/z* 389 (M), 302, 225; HRMS: calculated for C₂₂H₁₅NO₂S₂, 389.0544, found 389.0539; HPLC Purity (retention time): 100% (4.96 min)

(Z)-2-(4-oxo-5-((4'-phenoxybiphenyl-4-yl)methylene)-2-thioxothiazolidin-3-yl)acetic acid (5Cc)

¹H NMR (300 MHz, d₆-DMSO): δ 7.89 (s, 1H), 7.86 (d, J=8.6 Hz, 2H), 7.82 (d, J=8.6 Hz, 2H), 7.70 (m, 2H), 7.45 (m, 2H), 7.19 (t, J=7.5 Hz, 1H), 7.09 (m, 4H), 4.75 (s, 2H); EI-MS: *m/z* 447 (M), 302, 225; HPLC Purity (retention time): 98% (4.16 min)

(Z)-5-((4'-isopropoxybiphenyl-4-yl)methylene)thiazolidine-2,4-dione (7Aa)

¹H NMR (300 MHz, d₆-DMSO): δ 7.81 (m, 3H), 7.63–7.70 (m, 4H), 7.02 (d, J=8.6 Hz, 2H), 4.68 (m, 1H), 1.29 (d, J=5.7 Hz, 6H); EI-MS: *m/z* 339 (M), 297, 226; HPLC Purity (retention time): 94% (4.27 min)

(Z)-5-((4'-isopropoxybiphenyl-4-yl)methylene)-2-thioxothiazolidin-4-one (7Ab)

¹H NMR (300 MHz, d₆-DMSO): δ 7.82 (d, J=8.5 Hz, 2H), 7.63–7.70 (m, 5H), 7.02 (d, J=8.7 Hz, 2H), 4.68 (m, 1H), 1.28 (d, J=5.8 Hz, 6H); EI-MS: *m/z* 355 (M), 313, 226; HPLC Purity (retention time): 99% (4.60 min)

(Z)-2-(5-((4'-isopropoxybiphenyl-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid (7Ac)

¹H NMR (300 MHz, d₆-DMSO): δ 7.89 (s, 1H), 7.87(d, J=8.5 Hz, 2H), 7.68–7.75 (m, 4H), 7.03 (d, J=8.7 Hz, 2H), 4.75 (s, 2H), 4.68 (m, 1H), 1.28 (d, J=5.8 Hz, 6H); EI-MS: *m/z* 413 (M), 371, 226; HPLC Purity (retention time): 98% (3.73 min)

(Z)-5-((4'-allyloxy)biphenyl-4-yl)methylene)thiazolidine-2,4-dione (7Ba)

¹H NMR (300 MHz, d₆-DMSO): δ 7.82 (m, 3H), 7.68–7.75 (m, 4H), 7.06 (d, J=8.7 Hz, 2H), 6.05 (m, 1H), 5.42 (dd, J=17.5 Hz, 1.6 Hz, 1H), 5.27 (dd, J=10.5 Hz, 1.6 Hz, 1H), 4.63 (dd, J=5.1 Hz, 1.6 Hz, 2H); EI-MS: *m/z* 337 (M), 296, 225; HPLC Purity

(retention time): 95% (4.35 min)

(Z)-5-((4'-(allyloxy)biphenyl-4-yl)methylene)-2-thioxothiazolidin-4-one (7Bb)

¹H NMR (300 MHz, d₆-DMSO): δ 7.82 (d, J=8.3 Hz, 2H), 7.68 (m, 5H), 7.06 (d, J=8.7 Hz, 2H), 6.05 (m, 1H), 5.41 (dd, J=17.4 Hz, 1.6 Hz, 1H), 5.26 (dd, J=10.6 Hz, 1.6 Hz, 1H), 4.62 (dd, J=5.0 Hz, 1.6 Hz, 2H); EI-MS: *m/z* 353 (M), 312, 225; HPLC Purity (retention time): 98% (4.72 min)

(Z)-2-(5-((4'-(allyloxy)biphenyl-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid (7Bc)

¹H NMR (300 MHz, d₆-DMSO): δ 7.90 (s, 1H), 7.87 (d, J=8.4 Hz, 2H), 7.76 (m, 4H), 7.07 (d, J=8.7 Hz, 2H), 6.06 (m, 1H), 5.42 (dd, J=17.2 Hz, 1.6 Hz, 1H), 5.26 (dd, J=10.4 Hz, 1.6 Hz, 1H), 4.74 (s, 2H), 4.63 (dd, J=5.0 Hz, 1.6 Hz, 2H); EI-MS: *m/z* 411 (M), 370, 225; HPLC Purity (retention time): 96% (3.80 min)

(Z)-5-((4'-(cyclopropylmethoxy)biphenyl-4-yl)methylene)thiazolidine-2,4-dione (7Ca)

¹H NMR (300 MHz, d₆-DMSO): δ 7.81 (m, 3H), 7.67–7.74 (m, 4H), 7.03 (d, J=8.6 Hz, 2H), 3.85 (d, J=7.2 Hz, 2H), 1.23 (m, 1H), 0.57 (m, 2H), 0.33 (m, 2H); EI-MS: *m/z* 351 (M), 297, 226; HPLC Purity (retention time): 94% (4.38 min)

(Z)-5-((4'-(cyclopropylmethoxy)biphenyl-4-yl)methylene)-2-thioxothiazolidin-4-one (7Cb)

¹H NMR (300 MHz, d₆-DMSO): δ 7.81 (d, J=8.5 Hz, 2H), 7.67 (m, 5H), 7.02 (d, J=8.7 Hz, 2H), 3.86 (d, J=7.0 Hz, 2H), 1.23 (m, 1H), 0.57 (m, 2H), 0.33 (m, 2H); EI-MS: *m/z* 367 (M), 313, 280, 226; HPLC Purity (retention time): 98% (4.79 min)

(Z)-2-(5-((4'-(cyclopropylmethoxy)biphenyl-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid (7Cc)

¹H NMR (300 MHz, d₆-DMSO): δ 7.90 (s, 1H), 7.88 (d, J=8.4 Hz, 2H), 7.75 (m, 4H), 7.04 (d, J=8.6 Hz, 2H), 4.75 (s, 2H), 3.86 (d, J=7.1 Hz, 2H), 1.24 (m, 1H), 0.57 (m, 2H), 0.33 (m, 2H); EI-MS: *m/z* 425 (M), 371, 280, 226; HPLC Purity (retention time): 96% (3.98 min)

(Z)-5-((4'-butoxybiphenyl-4-yl)methylene)thiazolidine-2,4-dione (7Da)

¹H NMR (300 MHz, d₆-DMSO): δ 7.81 (m, 3H), 7.67–7.74 (m, 4H), 7.03 (d, J=8.7 Hz, 2H), 4.02 (t, J=6.7 Hz, 2H), 1.69 (m, 2H), 1.44 (m, 2H), 0.94 (t, J=7.5 Hz, 3H); EI-MS: *m/z* 353 (M), 297, 226; HPLC Purity (retention time): 96% (4.25 min)

(Z)-5-((4'-butoxybiphenyl-4-yl)methylene)-2-thioxothiazolidin-4-one (7Db)

¹H NMR (300 MHz, d₆-DMSO): δ 7.81 (d, J=8.3 Hz, 2H), 7.67 (m, 5H), 7.03 (d, J=8.8 Hz, 2H), 4.01 (t, J=6.6 Hz, 2H), 1.69 (m, 2H), 1.44 (m, 2H), 0.93 (t, J=7.5 Hz, 3H); EI-MS: *m/z* 369 (M), 282, 226; HPLC Purity (retention time): 94% (4.66 min)

(Z)-2-(5-((4'-butoxybiphenyl-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid (7Dc)

¹H NMR (300 MHz, d₆-DMSO): δ 7.89 (s, 1H), 7.87 (d, J=8.5 Hz,

2H), 7.76 (m, 4H), 7.05 (d, J=8.6 Hz, 2H), 4.75 (s, 2H), 4.02 (t, J=6.7 Hz, 2H), 1.69 (m, 2H), 1.45 (m, 2H), 0.94 (t, J=7.5 Hz, 3H); EI-MS: *m/z* 427 (M), 282, 226; HPLC Purity (retention time): 100% (3.84 min)

(Z)-5-((4'-isobutoxybiphenyl-4-yl)methylene)thiazolidine-2,4-dione (7Ea)

¹H NMR (300 MHz, d₆-DMSO): δ 7.82 (m, 3H), 7.67–7.74 (m, 4H), 7.03 (d, J=8.7 Hz, 2H), 3.79 (d, J=6.8 Hz, 2H), 2.04 (m, 1H), 0.98 (d, J=6.9 Hz, 6H); EI-MS: *m/z* 353 (M), 297, 226; HPLC Purity (retention time): 95% (4.31 min)

(Z)-5-((4'-isobutoxybiphenyl-4-yl)methylene)-2-thioxothiazolidin-4-one (7Eb)

¹H NMR (300 MHz, d₆-DMSO): δ 7.81 (d, J=8.7 Hz, 2H), 7.67 (m, 5H), 7.03 (d, J=8.7 Hz, 2H), 3.79 (d, J=6.5 Hz, 2H), 2.03 (m, 1H), 0.98 (d, J=6.7 Hz, 6H); EI-MS: *m/z* 369 (M), 313, 226; HPLC Purity (retention time): 100% (4.70 min)

(Z)-2-(5-((4'-isobutoxybiphenyl-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid (7Ec)

¹H NMR (300 MHz, d₆-DMSO): δ 7.89 (s, 1H), 7.87 (d, J=8.7 Hz, 2H), 7.76 (m, 4H), 7.05 (d, J=8.6 Hz, 2H), 4.75 (s, 2H), 3.80 (d, J=6.3 Hz, 2H), 2.03 (m, 1H), 0.99 (d, J=6.5 Hz, 6H); EI-MS: *m/z* 427 (M), 371, 282, 226; HPLC Purity (retention time): 98% (3.87 min)

(Z)-5-((4'-(benzyloxy)biphenyl-4-yl)methylene)thiazolidine-2,4-dione (7Fa)

¹H NMR (300 MHz, d₆-DMSO): δ 7.81 (m, 3H), 7.68–7.73 (m, 4H), 7.38–7.48 (m, 5H), 7.13 (m, 2H), 5.17 (s, 2H); ¹³C NMR (100 MHz, d₆-DMSO): 158.931, 158.662, 145.522, 143.978, 136.977, 134.531, 131.457, 131.193, 130.746, 130.218, 129.976, 128.514(×2), 128.423, 128.191, 128.041, 127.927, 127.726(×2), 126.701, 126.196, 115.488, 69.320; EI-MS: *m/z* 387 (M), 304, 225; HRMS: calculated for C₂₃H₁₇NO₃S, 387.0929, found 387.0936; HPLC Purity (retention time): 98% (4.52 min)

(Z)-5-((4'-(benzyloxy)biphenyl-4-yl)methylene)-2-thioxothiazolidin-4-one (7Fb)

¹H NMR (300 MHz, d₆-DMSO): δ 7.82 (d, J=8.5 Hz, 2H), 7.67 (m, 5H), 7.33–7.48 (m, 5H), 7.12 (d, J=8.6 Hz, 2H), 5.17 (s, 2H); EI-MS: *m/z* 403 (M), 304, 225; HRMS: calculated for C₂₃H₁₇NO₂S₂, 403.0701, found 403.0708; HPLC Purity (retention time): 100% (4.95 min)

(Z)-2-(5-((4'-(benzyloxy)biphenyl-4-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid (7Fc)

¹H NMR (300 MHz, d₆-DMSO): δ 7.90 (s, 1H), 7.88 (d, J=8.6 Hz, 2H), 7.76 (m, 4H), 7.34–7.48 (m, 5H), 7.15 (d, J=8.6 Hz, 2H), 5.18 (s, 2H), 4.75 (s, 2H); EI-MS: *m/z* 461 (M), 302, 225; HRMS: calculated for C₂₅H₁₉NO₄S₂, 461.0755, found 461.0762; HPLC Purity (retention time): 100% (4.09 min)

(Z)-5-((4'-(pyridin-3-ylmethoxy)biphenyl-4-yl)methylene)thiazolidine-2,4-dione (7Ga)

¹H NMR (300 MHz, d₆-DMSO): δ 8.72 (s, 1H), 8.58 (d, J=5.0 Hz,

1H), 7.97 (d, J=7.2 Hz, 1H), 7.82 (m, 3H), 7.67-7.74 (m, 4H), 7.48 (m, 1H), 7.15 (d, J=8.6 Hz, 2H), 5.24 (s, 2H); EI-MS: *m/z* 388 (M), 296, 289, 225; HPLC Purity (retention time): 98% (3.63 min)

(Z)-5-((4'-(pyridin-3-ylmethoxy)biphenyl-4-yl)methylene)-2-thioxothiazolidin-4-one (7Gb)

¹H NMR (300 MHz, *d*₆-DMSO): δ 8.73 (s, 1H), 8.59 (d, J=5.1 Hz, 1H), 7.97 (d, J=7.3 Hz, 1H), 7.81 (d, J=8.4 Hz, 2H), 7.67 (m, 5H), 7.50 (dd, J=7.3 Hz, J=5.1 Hz, 1H), 7.15 (d, J=8.8 Hz, 2H), 5.23 (s, 2H); EI-MS: *m/z* 404 (M), 262, 226; HPLC Purity (retention time): 96% (4.03 min)

(Z)-2-(4-oxo-5-((4'-(pyridin-3-ylmethoxy)biphenyl-4-yl)methylene)-2-thioxothiazolidin-3-yl)acetic acid (7Gc)

¹H NMR (300 MHz, *d*₆-DMSO): δ 8.73 (s, 1H), 8.58 (d, J=5.0 Hz, 1H), 7.98 (d, J=7.4 Hz, 1H), 7.91 (s, 1H), 7.89 (d, J=8.5 Hz, 2H), 7.79 (m, 4H), 7.52 (m, 1H), 7.18 (d, J=8.7 Hz, 2H), 5.24 (s, 2H), 4.76 (s, 2H); EI-MS: *m/z* 462 (M), 370, 302, 225; HPLC Purity (retention time): 99% (3.30 min)

(Z)-5-((4'-phenethoxybiphenyl-4-yl)methylene)thiazolidine-2,4-dione (7Ha)

¹H NMR (300 MHz, *d*₆-DMSO): δ 7.81 (m, 3H), 7.67-7.74 (m, 4H), 7.23-7.32 (m, 5H), 7.05 (d, J=8.7 Hz, 2H), 4.25 (t, J=6.8 Hz, 2H), 3.05 (t, J=6.8 Hz, 2H); EI-MS: *m/z* 401 (M), 302, 297, 226; HPLC Purity (retention time): 98% (4.44 min)

(Z)-5-((4'-phenethoxybiphenyl-4-yl)methylene)-2-thioxothiazolidin-4-one (7Hb)

¹H NMR (300 MHz, *d*₆-DMSO): δ 7.80 (d, J=8.5 Hz, 2H), 7.67 (m, 5H), 7.23-7.33 (m, 5H), 7.04 (d, J=8.9 Hz, 2H), 4.24 (t, J=6.9 Hz, 2H), 3.05 (t, J=6.9 Hz, 2H); EI-MS: *m/z* 417 (M), 313, 226; HPLC Purity (retention time): 96% (4.89 min)

(Z)-2-(4-oxo-5-((4'-phenethoxybiphenyl-4-yl)methylene)-2-thioxothiazolidin-3-yl)acetic acid (7Hc)

¹H NMR (300 MHz, *d*₆-DMSO): δ 7.89 (s, 1H), 7.87 (d, J=8.5 Hz, 2H), 7.76 (m, 4H), 7.25-7.34 (m, 5H), 7.05 (d, J=8.7 Hz, 2H), 4.75 (s, 2H), 4.25 (t, J=6.9 Hz, 2H), 3.05 (t, J=6.9 Hz, 2H); EI-MS: *m/z* 475 (M), 371, 226; HPLC Purity (retention time): 96% (4.05 min)

(Z)-5-((4'-(3-phenylpropoxy)biphenyl-4-yl)methylene)thiazolidine-2,4-dione (7Ia)

¹H NMR (300 MHz, *d*₆-DMSO): δ 7.81 (m, 3H), 7.67-7.75 (m, 4H), 7.18-7.30 (m, 5H), 7.04 (d, J=8.7 Hz, 2H), 4.02 (t, J=6.5 Hz, 2H), 2.75 (t, J=6.9 Hz, 2H), 2.01 (m, 2H); EI-MS: *m/z* 415 (M), 344, 297, 226; HPLC Purity (retention time): 98% (4.41 min)

(Z)-5-((4'-(3-phenylpropoxy)biphenyl-4-yl)methylene)-2-thioxothiazolidin-4-one (7Ib)

¹H NMR (300 MHz, *d*₆-DMSO): δ 7.81 (d, J=8.4 Hz, 2H), 7.67 (m, 5H), 7.18-7.29 (m, 5H), 7.04 (d, J=8.7 Hz, 2H), 4.01 (t, J=6.3 Hz, 2H), 2.75 (t, J=6.9 Hz, 2H), 2.03 (m, 2H); EI-MS: *m/z* 431 (M), 344, 313, 226; HPLC Purity (retention time): 99% (4.83 min)

(Z)-2-(4-oxo-5-((4'-(3-phenylpropoxy)biphenyl-4-yl)methylene)-2-thioxothiazolidin-3-yl)acetic acid (7Ic)

¹H NMR (300 MHz, *d*₆-DMSO): δ 7.89 (s, 1H), 7.87 (d, J=8.5 Hz, 2H), 7.76 (m, 4H), 7.18-7.30 (m, 5H), 7.05 (d, J=8.6 Hz, 2H), 4.75 (s, 2H), 4.03 (t, J=6.2 Hz, 2H), 2.75 (t, J=6.7 Hz, 2H), 2.04 (m, 2H); EI-MS: *m/z* 489 (M), 450, 332, 226; HPLC Purity (retention time): 97% (4.00 min)

Acknowledgements

This work was supported by the 863 High-Tech Research and Development Program of China (Grant 2006AA02Z315 and 2008AA02Z105), the National S&T Major Projects "Key New Drug Creation and Manufacturing Program" of China (No 2009ZX09301-001, 2009ZX09302-001 and 2009ZX09501-010) and the Public Service Platform Foundation of Shanghai Ministry of Science and Technology (08DZ2291300 and 09DZ2291200).

Author contribution

Jing-kang SHEN and Jia LI designed the research; Zhang LIU, Qian CHAI, Yuan-yuan LI, Qiang Shen, Lan-ping MA, Jing-ya LI, Li-na ZHANG, and Li SHENG performed the research; Xin WANG contributed new analytical tools and reagents; Zhang LIU, Qian CHAI and Lan-ping MA analyzed data; Zhang LIU wrote the paper.

References

- Hunter T. Signaling – 2000 and Beyond. *Cell* 2000; 100: 113–27.
- Tonks NK, Neel BG. Combinatorial control of the specificity of protein tyrosine phosphatases. *Curr Opin Cell Biol* 2001; 13: 182–95.
- Kappert K, Peters KG, Bohmer FD, Ostman A. Tyrosine phosphatases in vessel wall signaling. *Cardio Vasc Res* 2005; 65: 587–98.
- Stoker AW. Protein tyrosine phosphatases and signaling. *J Endocrinol* 2005; 185: 19–33.
- Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. *Nat Rev Mol Cell Bio* 2006; 7: 833–46.
- Wang WJ, Kuo JC, Ku W, Lee YR, Lin FC, Chang YL, et al. The tumor suppressor *dapk* is reciprocally regulated by tyrosine kinase *src* and phosphatase *LAR*. *Mol Cell* 2007; 27: 701–16.
- Zhang ZY. Protein tyrosine phosphatases: prospects for therapeutics. *Curr Opin Chem Biol* 2001; 5: 416–23.
- Hooft van Huijsduijnen R, Bombrun A, Swinnen D. Selecting protein tyrosine phosphatases as drug targets. *Drugs Discov Today* 2002; 7: 1013–9.
- Hendriks WJ, Elson A, Harroch S, Stoker AW. Protein tyrosine phosphatases: functional inferences from mouse models and human diseases. *FEBS J* 2008; 275: 816–30.
- Julien SG. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. *Nat Genet* 2007; 39: 338–46.
- Johnson TO, Ermolieff J, Jirousek MR. Protein tyrosine phosphatase 1B inhibitors for diabetes. *Nat Rev Drug Discov* 2002; 1: 696–709.
- Liu G, Trevillyan JM. Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes. *Curr Opin Investig Drugs* 2002; 3: 1608–16.
- Tobin JF, Tam S. Recent advances in the development of small molecule inhibitors of PTP1B for the treatment of insulin resistance and type 2 diabetes. *Curr Opin Drug Discov Devel* 2002; 5: 500–12.

- 14 Zhang Z. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. *Annu Rev Pharmacol Toxicol* 2002; 42: 209–34.
- 15 Zhang Z, Zhou B, Xie L. Modulation of protein kinase signaling by protein phosphatases and inhibitors. *Pharmacol Therap* 2002; 93: 307–17.
- 16 Kennedy BP, Ramachandran C. Protein tyrosine phosphatase-1B in diabetes. *Biochem Pharmacol* 2000; 60: 877–83.
- 17 Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, *et al*. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase 1B gene. *Science* 1999; 283: 1544–8.
- 18 Klamann LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, *et al*. Increased energy expenditure decreased adiposity and tissue-specific insulin sensitivity in protein – tyrosine phosphatase 1B deficient mice. *Mol Cell Biol* 2000; 20: 5479–89.
- 19 Zinker BA, Rondinone CM, Trevillyan JM, Gum RJ, Clampit JE, Waring JF. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. *Proc Natl Acad Sci USA* 2002; 99: 11357–62.
- 20 Gum RJ, Gaede LL, Koterski SL, Heindel M, Clampit JE, Zinker BA, *et al*. Reduction of protein tyrosine phosphatase 1b increases insulin-dependent signaling in ob/ob mice. *Diabetes* 2003; 52: 21–8.
- 21 Lessard L, Stuiblé M, Tremblay ML. The two faces of PTP1B in cancer. *Biochim Biophys Acta* 2010; 1804: 613–9.
- 22 Zhang S, Zhang ZY. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. *Drug Discov Today* 2007; 12: 373–81.
- 23 Lee S, Wan Q. Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B. *Med Res Rev* 2007; 27: 553–73.
- 24 Zhang Y, Li Y, Guo YW, Jiang HL, Shen X. A sesquiterpene quinone, dysidine, from the sponge *Dysidea villosa*, activates the insulin pathway through inhibition of PTPases. *Acta Pharmacol Sin* 2009; 30: 333–45.
- 25 Shi L, Yu HP, Zhou YY, Du JQ, Shen Q, Li JY, *et al*. Discovery of a novel competitive inhibitor of PTP1B by high-throughput screening. *Acta Pharmacol Sin* 2008; 29: 278–84.
- 26 Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H. Fragment-based lead discovery using X-ray crystallography. *J Med Chem* 2005; 48: 403–13.
- 27 Wilson DP, Wan ZK, Xu WX, Kirincich SJ, Follows BC, Joseph-McCarthy D, *et al*. Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site. *J Med Chem* 2007; 50: 4681–98.
- 28 Hussain M, Ahmed V, Hill B, Ahmed Z, Taylor SD. A re-examination of the difluoromethanesulfonic acid group as a phosphotyrosine mimic for PTP1B inhibition. *Bioorg Med Chem* 2008; 16: 6764–77.
- 29 Reddy KA, Lohray BB, Bhushan V, Bajji AC, Reddy KV, Reddy PR, *et al*. Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones. *J Med Chem* 1999; 42: 1927–40.
- 30 Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. *J Med Chem* 2000; 43: 527–50.
- 31 Costantino L, Rastelli G, Vianello P, Cignarella G, Barlocco D. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. *Med Res Rev* 1999; 19: 3–23.
- 32 Malamas MS, Sredy J, Gunawan I, Mihan B, Sawicki DR, Seestaller L, *et al*. New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. *J Med Chem* 2000; 43: 995–1010.
- 33 Liu Z, Huang Y, Zhang W, Ma LP, Li JY, Wang X, *et al*. Soluble polymer-supported synthesis of 5-arylidene thiazolidinones and pyrimidinones using a novel traceless linker strategy. *J Comb Chem* 2008; 10: 632–6.
- 34 Zhang W, Hong D, Zhou Y, Zhang Y, Shen Q, Li JY, *et al*. Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B enhancing insulin receptor phosphorylation and stimulating glucose uptake. *Biochim Biophys Acta* 2006; 1760: 1505–12.